Medical Doctor Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Mehrdad Abbassian

Geriatric Psychiatry Westmont, IL Medical Doctor

NPI 1871527846 CMS profile 1043077

540 Oakmont Ln, Westmont, IL 60559

Open in the dashboard

General payments

$292

2 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Mehrdad Abbassian of Westmont, IL is reported in the CMS Open Payments database as having received $292 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Geriatric Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $174 1
2021 General $118 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mehrdad Abbassian
  • Geriatric Psychiatry median
  • Middle half of Geriatric Psychiatry
  • National median

In program year 2025, general payments to Mehrdad Abbassian were reported at $0. Among 188 Geriatric Psychiatry profiles paid that year, the median was $125 and the middle half received between $52 and $515.

Show as a table
Year Mehrdad Abbassian Geriatric Psychiatry median Middle half National median
2019 $0 $151 $47–$484 $163
2020 $0 $112 $30–$410 $114
2021 $118 $122 $35–$550 $132
2022 $0 $133 $54–$557 $149
2023 $0 $138 $61–$485 $160
2024 $174 $127 $51–$572 $164
2025 $0 $125 $52–$515 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Stryker Corporation $174 1 payment
  2. ACADIA Pharmaceuticals Inc $118 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $292 2 payments
Products named General payments · program years 2021–2024
  1. ALPHAVENT $174 1 payment
  2. NUPLAZID $118 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

732

Median for Geriatric Psychiatry: 897

Drug cost

$12,697

Median for Geriatric Psychiatry: $35,920

Branded share of claims

7%

Median for Geriatric Psychiatry: 14.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Quetiapine Fumarate Generic 156 $2,386
Memantine Hcl Generic 51 $1,925
Mirtazapine Generic 59 $1,343
Donepezil Hcl Generic 75 $1,268
Escitalopram Oxalate Generic 98 $1,167
Duloxetine Hcl Generic 40 $797
Sertraline Hcl Generic 62 $691
Risperidone Generic 24 $506
Olanzapine Generic 30 $500
Bupropion Hcl Sr Bupropion Hcl Brand 19 $463

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 158 Part D prescribers listed as Geriatric Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$12,135

Medicare's payments for the services billed

Medicare patients

147

Average age 83

Services billed

191

108 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Alzheimer's or dementia 75%
Arthritis 66%
Heart failure 48%
Chronic kidney disease 48%
Ischemic heart disease 43%
Atrial fibrillation 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record